EBOS, Australia’s largest listed healthcare, pharmaceuticals, and pet products company, is experiencing a series of senior executive departures amid ongoing operational challenges and share price pressure. The company’s shares have remained around $15, significantly below the near $40 peak reached under former CEO John Cullity.

Kristine James, who led EBOS’s $15 billion medical technology division as chief executive, recently resigned and is currently serving out her notice period. A company spokesperson attributed her departure to a desire to spend more time with family. Efforts are underway to identify a successor, but internal sources suggest additional senior exits from the medical technology segment may follow.

This week also saw the exits of Alison Van Wyk, executive general manager of ProPharma—a pharmaceutical wholesale business within EBOS—and Sophie Prentice, executive general manager of healthcare logistics. Van Wyk is returning to the New Zealand-listed Green Cross Health network, while Prentice is relocating to Singapore to accompany her husband’s employment. Bradley James, the current executive general manager for healthcare partnerships, is expected to assume Prentice’s responsibilities.

Reports of widespread job cuts have emerged, with some media outlets claiming that as many as 150 finance and 100 IT roles are being eliminated, outsourced, or replaced by artificial intelligence. An EBOS spokesman contested these figures, stating that fewer than 50 positions would be affected. Nevertheless, insiders allege that a combination of forced exits, redundancies, and minimal transparency is fostering low morale across the organisation. One insider described a workplace environment where employees are suddenly absent without explanation, leaving colleagues to absorb added workloads.

EBOS operates across four distinct sectors: healthcare distribution, retail pharmacies, medical technology, and animal care. Sources indicate that internal sentiment toward the company’s headquarters is largely negative, with a perceived preference for the healthcare and pharmaceutical wholesale division, Symbion, which is referred to internally as the company’s “cash cow.” Conversely, TerryWhite Chemmart, one of EBOS’s flagship retail pharmacy brands, is reportedly viewed by corporate executives as a “problem child” due to its limited engagement with head office.

Employee frustration is exacerbated by successive redundancy rounds and widespread burnout. Describing the corporate atmosphere as “extremely dark,” one source cited pervasive fear among staff. Leadership has also come under scrutiny, with CEO Adam Hall’s approach characterised by some insiders as “unpredictable.” However, many within the company trace current difficulties back to 2023, when EBOS lost a major $1.9 billion Chemist Warehouse supply contract to rival Sigma Healthcare, a setback still affecting the firm’s strategic trajectory.